Next Article in Journal
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia
Previous Article in Journal
Molecular Classification of Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma Cases and Association with Outcomes in Morocco
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hemato
Volume 5
Issue 4
10.3390/hemato5040030
hemato-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

by
Lisa Blackburn
,
Anthony Mansour
,
Qiuhong Zhao
,
Francesca Cottini
,
Abdullah Khan
,
Naresh Bumma
,
Srinivas Devarakonda
,
Elvira Umyarova
,
Ashley E. Rosko
,
Jennifer Vaughn
,
Nidhi Sharma
and
Don M. Benson, Jr.
*
Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, 308 Wiseman Hall, 400 W. 10th Avenue, Columbus, OH 43210, USA
*
Author to whom correspondence should be addressed.
Hemato 2024, 5(4), 407-419; https://doi.org/10.3390/hemato5040030
Submission received: 14 August 2024 / Revised: 2 October 2024 / Accepted: 5 October 2024 / Published: 14 October 2024
(This article belongs to the Section Plasma Cell Disorders)
Browse Figures
Versions Notes

Abstract

Background—Autologous stem cell transplant (ASCT) is integral to the treatment of multiple myeloma (MM), although its absolute necessity in first remission has been recently questioned. We report real-world factors that influence clinical decision-making and outcomes from ASCT in 733 patients with MM. Results—Similar to recent prospective data, we found a significant progression-free survival (PFS) benefit with early versus deferred ASCT (median PFS of 5.1 years versus 2.6 years, p < 0.001); however, there was no significant difference in overall survival (median OS of 8.3 years and 8.6 years, p = 0.21). Patient preference, age, marital status, body mass index, and comorbidities influence ASCT timing. Conclusion—These findings highlight the emerging role of an individualized, shared decision-making model regarding the timing of ASCT between patients and physicians with the myriad of treatment options available in the contemporary era.
Keywords: myeloma; early transplant; deferred transplant; outcomes; decision-making myeloma; early transplant; deferred transplant; outcomes; decision-making

Share and Cite

MDPI and ACS Style

Blackburn, L.; Mansour, A.; Zhao, Q.; Cottini, F.; Khan, A.; Bumma, N.; Devarakonda, S.; Umyarova, E.; Rosko, A.E.; Vaughn, J.; et al. Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Hemato 2024, 5, 407-419. https://doi.org/10.3390/hemato5040030

AMA Style

Blackburn L, Mansour A, Zhao Q, Cottini F, Khan A, Bumma N, Devarakonda S, Umyarova E, Rosko AE, Vaughn J, et al. Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Hemato. 2024; 5(4):407-419. https://doi.org/10.3390/hemato5040030

Chicago/Turabian Style

Blackburn, Lisa, Anthony Mansour, Qiuhong Zhao, Francesca Cottini, Abdullah Khan, Naresh Bumma, Srinivas Devarakonda, Elvira Umyarova, Ashley E. Rosko, Jennifer Vaughn, and et al. 2024. "Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma" Hemato 5, no. 4: 407-419. https://doi.org/10.3390/hemato5040030

APA Style

Blackburn, L., Mansour, A., Zhao, Q., Cottini, F., Khan, A., Bumma, N., Devarakonda, S., Umyarova, E., Rosko, A. E., Vaughn, J., Sharma, N., & Benson, D. M., Jr. (2024). Real World Predictors, Timing, and Outcomes of Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Hemato, 5(4), 407-419. https://doi.org/10.3390/hemato5040030

Article Metrics

Back to TopTop